RapidPulse Emerges in the Ischemic Stroke Therapy Field

GoodIdeas IMG_Jun232021at33528PM.jpg
The company has raised $15 million in a series A round.

There’s a new player in the Ischemic Stroke Therapy market. RapidPulse, a company spun out of Syntheon, a medical device incubator, has launched.

The Miami, FL-based company raised $15 million in a series A round to advance its RapidPulse Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

RapidPulse said its device includes an aspiration pump to allow rapid and consistent removal of blood clots from the brain.

The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the U.S.”

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.